185 related articles for article (PubMed ID: 15754125)
1. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments.
Achiron A; Barak Y; Gail M; Mandel M; Pee D; Ayyagari R; Rotstein Z
Breast Cancer Res Treat; 2005 Feb; 89(3):265-70. PubMed ID: 15754125
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Lebrun C; Debouverie M; Vermersch P; Clavelou P; Rumbach L; de Seze J; Wiertlevski S; Defer G; Gout O; Berthier F; Danzon A
Mult Scler; 2008 Apr; 14(3):399-405. PubMed ID: 18420778
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
4. The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS.
Pöllmann W; Erasmus LP; Feneberg W; Straube A
Neurology; 2006 Jan; 66(2):275-7. PubMed ID: 16434675
[TBL] [Abstract][Full Text] [Related]
5. [Immunomodulatory treatments for multiple sclerosis: lessons from direct comparative studies].
Ouallet JC
Rev Neurol (Paris); 2010 Jan; 166(1):21-31. PubMed ID: 19596382
[TBL] [Abstract][Full Text] [Related]
6. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
7. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
Correale J; Cristiano E
Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
[TBL] [Abstract][Full Text] [Related]
8. Reduced cancer incidence among patients with schizophrenia.
Barak Y; Achiron A; Mandel M; Mirecki I; Aizenberg D
Cancer; 2005 Dec; 104(12):2817-21. PubMed ID: 16288491
[TBL] [Abstract][Full Text] [Related]
9. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
10. [Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo].
Tedeholm H; Skoog B; Hillert J; Runmarker B; Stawiarz L; Oluf A
Lakartidningen; 2007 May 30-Jun 3; 104(22):1684-8. PubMed ID: 17601317
[No Abstract] [Full Text] [Related]
11. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
[TBL] [Abstract][Full Text] [Related]
12. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis.
Lage MJ; Castelli-Haley J; Oleen-Burkey MA
Work; 2006; 27(2):143-51. PubMed ID: 16971761
[TBL] [Abstract][Full Text] [Related]
13. [Recent therapeutic strategy for multiple sclerosis].
Itoyama Y
Rinsho Shinkeigaku; 2001 Dec; 41(12):1214-7. PubMed ID: 12235841
[TBL] [Abstract][Full Text] [Related]
14. Non-specific immunosuppressants in the treatment of multiple sclerosis.
Confavreux C; Vukusic S
Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
[TBL] [Abstract][Full Text] [Related]
15. Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.
Neuhaus O; Stüve O; Archelos JJ; Hartung HP
J Neurol Sci; 2005 Jun; 233(1-2):173-7. PubMed ID: 15949504
[TBL] [Abstract][Full Text] [Related]
16. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
17. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
[TBL] [Abstract][Full Text] [Related]
19. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
20. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.
Jacobs EJ; Thun MJ; Bain EB; Rodriguez C; Henley SJ; Calle EE
J Natl Cancer Inst; 2007 Apr; 99(8):608-15. PubMed ID: 17440162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]